Alpha-pharma Healthcare Private Limited

Alpha-Pharma Healthcare Private Limited, established on January 15, 2014, is a private unlisted company headquartered in Ambarnath, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U74999MH2014FTC252081. As of March 6, 2026, Alpha-Pharma has an authorized capital of ₹20.00 crore and a paid-up capital of ₹18.98 crore. The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its product portfolio spans three therapeutic categories: Diabetes & Endocrine, Advanced Diabetes Medications, and Advanced Oncology.

In the fiscal year 2022, Alpha-Pharma reported a 32.16% increase in revenue, a 232.23% rise in profit, and a 43.26% growth in net worth, indicating robust financial performance. The company's mission is to improve the quality of life by expanding global access to trusted, affordable therapies, combining scientific rigor, compliant manufacturing, and responsible supply to reduce the overall cost of care. (alpha-pharma.co)

Alpha-Pharma operates a manufacturing facility located at Unit 11, Mukta Heights, B-Wing, Near Shashwat Park, Badlapur West, Ambarnath, Maharashtra, 421503, India. The plant is compliant with current Good Manufacturing Practices (cGMP), ensuring the production of high-quality pharmaceutical formulations. The facility specializes in the production of finished dosage forms, including tablets, capsules, syrups, and injections, catering to various therapeutic areas such as Diabetes & Endocrine, Advanced Diabetes Medications, and Advanced Oncology.

Alpha-Pharma's leadership comprises two directors:

• Jacob Sporon Fiedler: Appointed on January 15, 2014, he has been associated with the company since its inception.

• Hrangdanglien: Joined as a director on May 27, 2019, bringing valuable experience to the leadership team.

Alpha-Pharma's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across three therapeutic categories:

• Diabetes & Endocrine: 59.8% of total exports, with top products like Empagliflozin and Semaglutide.

• Advanced Diabetes Medications: 34.0% of total exports, featuring products such as Semaglutide.

• Advanced Oncology: 6.2% of total exports, including products like Tofacitinib.

The company's export value stands at $263,000 USD, with 215 shipments, indicating a focused product portfolio. Notably, Empagliflozin holds a 2.3% market share, ranking 10th, while Semaglutide has a 1.8% market share, ranking 12th. Tofacitinib, with a 0.4% market share, also ranks 12th. Alpha-Pharma's strategic focus on these therapeutic areas aligns with global health priorities, particularly in managing diabetes and oncology conditions.

Alpha-Pharma's export strategy includes targeting emerging markets in Africa, Latin America, and Southeast Asia. By obtaining World Health Organization (WHO) prequalification, the company enhances its credibility and facilitates access to these regions. The prequalification process involves rigorous evaluation of manufacturing practices, product quality, and compliance with international standards, enabling Alpha-Pharma to meet the specific regulatory requirements of these markets. This strategic approach positions the company to expand its global footprint and contribute to improving healthcare access in underserved regions.

Alpha-Pharma's export portfolio is concentrated on three therapeutic categories, with a significant emphasis on Diabetes & Endocrine (59.8%) and Advanced Diabetes Medications (34.0%). This concentration suggests a strategic focus on addressing prevalent health issues related to diabetes and endocrine disorders. While the company has a presence in Advanced Oncology (6.2%), the limited diversification in therapeutic areas may expose Alpha-Pharma to market risks associated with these specific segments. To mitigate potential risks, the company could consider expanding its product portfolio to include other therapeutic areas, thereby enhancing its market resilience and growth prospects.

Alpha-Pharma's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across three therapeutic categories:

• Diabetes & Endocrine: 59.8% of total exports, with top products like Empagliflozin and Semaglutide.

• Advanced Diabetes Medications: 34.0% of total exports, featuring products such as Semaglutide.

• Advanced Oncology: 6.2% of total exports, including products like Tofacitinib.

The company's export value stands at $263,000 USD, with 215 shipments, indicating a focused product portfolio. Notably, Empagliflozin holds a 2.3% market share, ranking 10th, while Semaglutide has a 1.8% market share, ranking 12th. Tofacitinib, with a 0.4% market share, also ranks 12th. Alpha-Pharma's strategic focus on these therapeutic areas aligns with global health priorities, particularly in managing diabetes and oncology conditions.

Alpha-Pharma's commitment to quality is evident in its adherence to current Good Manufacturing Practices (cGMP). The company has introduced new artworks and security features for batches manufactured from March 2022 onward, including product authentication via QR codes and scratch codes. (alpha-pharma.co) While specific certifications such as WHO prequalification and EU GMP certificates are not explicitly mentioned, the company's focus on quality manufacturing practices suggests alignment with international standards. To enhance its global competitiveness, Alpha-Pharma could pursue formal certifications from WHO and EU GMP, further validating its commitment to quality and facilitating access to regulated markets.

Alpha-Pharma operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility is located in Ambarnath, Maharashtra, and is registered with the Registrar of Companies (ROC) Mumbai II under the CIN U74999MH2014FTC252081. The facility complies with current Good Manufacturing Practices (cGMP), ensuring the production of high-quality pharmaceutical formulations. While specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not provided, the company's adherence to cGMP and regulatory standards indicates a commitment to compliance with Indian regulatory requirements.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Alpha-Pharma Healthcare Private Limited. The company's adherence to current Good Manufacturing Practices (cGMP) and its focus on quality manufacturing practices suggest a proactive approach to regulatory compliance. However, without specific records, it is advisable for stakeholders to conduct thorough due diligence to ensure the company's ongoing compliance with regulatory standards.

Alpha-Pharma operates in the competitive pharmaceutical export market, focusing on finished formulations in therapeutic areas such as Diabetes & Endocrine, Advanced Diabetes Medications, and Advanced Oncology. While specific competitors are not identified in the available data, the company's emphasis on quality manufacturing practices and cost-efficient therapies positions it to compete effectively in these segments. To enhance its market position, Alpha-Pharma could consider expanding its product portfolio and exploring new therapeutic areas, thereby broadening its competitive edge.

Alpha-Pharma's key differentiators include its commitment to improving the quality of life by expanding global access to trusted, affordable therapies. The company emphasizes compliant manufacturing and responsible supply to reduce the overall cost of care. Additionally, Alpha-Pharma has introduced micro tablets, a series of micronized tablets designed to achieve superior particle size distribution, enhancing dissolution and bioavailability profiles. (alpha-pharma.co) These innovations reflect the company's dedication to quality and patient-centric solutions.

Alpha-Pharma's current strategic direction focuses on the production and export of finished pharmaceutical formulations in specific therapeutic areas, including Diabetes & Endocrine, Advanced Diabetes Medications, and Advanced Oncology. The company's commitment to quality manufacturing practices and cost-efficient therapies aligns with global healthcare needs.